A revolutionary system for the treatment of glaucoma has just been developed in Switzerland


World discovery straight from Lausanne
This invention, named eyeWatch, has been developed through collaboration between Prof. Stergiopulos, Dr. Mermoud and Dr. Adan Villamarin, founder of Rheon Medical, a spin-off of the EPFL (École polytechnique fédérale de Lausanne). Their first attempts date back to 2010-2011 and were followed by lengthy studies and trials to validate the total biocompatibility and sterility of the device. “We had to be absolutely certain that it would function in the eye in the long term. After all the studies had been completed successfully, SwissMedic, the Swiss agency for the authorization and supervision of therapeutic products, allowed us to implant the device on the first patient in September 2015. (The selection of patients is based on very strict criteria: only those who would lose the sight of an eye without the new treatment can be considered). Four patients have so far received the implant and are doing extremely well. We have the right – and the duty – to treat 26 more in 2016. Once 30 patients have been treated, SwissMedic should grant authorization for the implant to be brought to the market in Switzerland and very soon in Europe.”


Read the full press release.

About the specialist

Prof méd. André Mermoud

FMH Specialist in ophthalmology and ophthalmic surgery